RuiYi, Genor sign RYI-008 development deal in China

The novel anti-IL-6 monoclonal antibody RYI-008 is believed to have a potential to define new paradigm in the treatment of autoimmune diseases and cancer.

RuiYi president and CEO Paul Grayson said, "RYI-008, with its unprecedented femtamolar potency and amazing long half-life has a therapeutic profile of once monthly, low milligram, subcutaneous dosing."

Genor BioPharma CEO Joe Zhou said, "The selection by RuiYi and Genor of RYI-008 for development shows a unique understanding of a changing healthcare environment in China where the cost-effective delivery of novel efficacious medicines is of significant importance."

RYI-008, also known as ARGX-109, with unique pharmacologic profile was discovered by arGEN-X, Ghent Belgium, utilizing the arGEN-X SIMPLE Antibody technology.